Download Steinfeld_05

Issue: February 2005
Secretion Removal in the ICU
by Jon Steinfeld, MD
In the ICU, the inability to manage secretions can lead to prolonged mechanical ventilation
and hospitalization.
Article Tools
Email This Article
Reprint This Article
Write the Editor
Print This Article
Airway secretions protect the airway epithelium from infection and mechanical damage.
Mucus traps foreign particles, including infectious materials, and acts as a transport medium
to clear the lungs of harmful objects. Impairments in mucociliary clearance lead to
ventilation-perfusion mismatching, atelectasis, and pneumonia. In the intensive care unit (ICU), the inability to manage
these secretions can lead to prolonged mechanical ventilation and hospitalization. Excessive secretions can create
mucous plugging, necessitating increased ventilatory support.
The two main modalities of airway clearance are physical and pharmacological. Patients should be approached on a
case-by-case basis to determine which interventions are necessary. Ventilator-management strategies may also aid
airway clearance.
Physical Airway Clearance
Physical airway clearance can be further divided into therapies directed at the chest wall or the airway lumen. Many of
these therapies have become the standard of care in the ICU and at home, despite the paucity of well-controlled
studies.1 Chest wall therapies include hand-percussion chest physiotherapy (CPT), postural drainage, and high-frequency
chest-wall (HFCW) devices.
Hand percussive CPT for airway clearance has been well documented in cystic fibrosis (CF) care.2,3 This technique may
be performed with a cupped hand, plastic face mask, or specially made percussors and vibratory devices. Sessions are
typically very time intensive and physically demanding. Patient comfort should always be kept in mind, along with
oxygen saturation and heart rate. There has been some debate as to whether there is sufficient benefit to justify routine
CPT in CF.4 Despite this controversy, data from CF studies have been extrapolated to other conditions with poor
mucociliary clearance. For example, CPT in asthma exacerbations should be reserved for the removal of retained
secretions due to the high risk of inducing bronchospasm. Similarly, CPT for atelectasis has not been studied intensively
and should not be considered the standard of care.5
Postural drainage has been paired with CPT in the belief that certain head-down positions would aid mucus clearance.
These positions may induce gastroesophageal reflux and, in turn, aggravate lung disease. 6 A recent study7 showed that
patients with CF who practiced postural drainage with CPT had worse chest-radiograph scores and pulmonary-function
tests after 5 years than matched patients who performed CPT without head-down positioning. These patients, however,
were healthy, nonhospitalized children with CF. In the intubated patient, Berney et al8 found that a head-down position
during CPT improved sputum production, peak expiratory flow, and lung compliance, when compared with results for
patients lying on their sides. This study is encouraging for patients in the ICU and should be repeated with a larger
sample size.
A large amount of effort and money has been invested in HFCW devices. These work through a vest that rapidly inflates
and deflates. HFCW devices are attractive, since the patient can operate them and achieve greater independence.
Studies2,9,10 in patients with CF have shown results similar to those for CPT. HFCW devices have yet to be studied in
acute respiratory care.
Physical therapies directed at the airway include intra-percussive pulmonary ventilation (IPV), the use of cough-assisting
devices, and flexible bronchoscopy. Due to the discomfort associated with chest-wall therapies, investigators have
attempted to improve mucus clearance directly. IPV delivers pressures oscillating between 5 and 35 cm H2O through a
mouthpiece to the airways in order to loosen mucus and improve clearance.10 IPV, like HFCW devices, has exhibited
clinical results and patient preferences similar to those for CPT.2
Devices to assist coughing have been available for decades. They provide a large inspiration followed by a negative
pressure to improve mucus clearance in patients with poor diaphragmatic function. The use of cough-assisting devices
has been shown to improve cough and prevent pulmonary complications.11,12 Patients with weak coughs and atelectasis
warrant a trial of a cough-assisting device before more invasive procedures are attempted.
Flexible bronchoscopy is a well-tolerated, minimally invasive procedure that is most frequently used for diagnostic
purposes.13 A recent study13 showed that, in pediatric ICU patients with lobar or segmental lung collapse, 75% had reexpansion visible in chest radiographs after flexible bronchoscopy.
Other therapies, such as positive expiratory pressure, active cycle of breathing, and autogenic breathing, are used more
frequently to maintain lung function in the chronic setting than during acute exacerbations. Patients in the ICU are
frequently unable to cooperate with these techniques.
Pharmacological Airway Clearance
Airway secretions are affected by many different medications. Some medications alter the volume of secretions, while
others change their characteristics. Care should be taken to ensure that medications given for nonrespiratory purposes
do not lead to further respiratory compromise.
b-Adrenergic agonists have been found to increase ciliary beat frequency.14 Long-acting b-agonists also have prolonged
effects on ciliary activity.15 In vivo studies16 have shown increases in alveolar fluid clearance as high as 100% in animals
with increased b-agonist receptors. These data support the use of b-agonists for airway clearance, even in the absence
of bronchospasm.
Recombinant human deoxyribonuclease (DNase) has been used for years in the treatment of CF. 17,18 By decreasing the
viscosity of mucus, DNase has been shown to improve lung function in patients with CF.19 DNase has also been shown to
decrease the viscosity of mucus in patients with non-CF bronchitis.20 Despite a lack of controlled trials, there are multiple
reports of successful DNase use in the ICU.21 One such report22 found rapid improvement in a patient in status
asthmaticus who had undergone flexible bronchoscopy that failed to remove plugs of mucus. DNase was given through
the endotracheal tube, and the patient had rapid clinical improvement. Another group23 reported success with DNase
given through a flexible bronchoscope to treat CF patients with isolated mucous plugging who had not responded to
prolonged courses of antibiotics and aggressive CPT.
Mucolytics and expectorants have exhibited mixed results in altering mucociliary clearance and have not been used
extensively in the ICU.24 One popular expectorant, guaifenesin, has been found to have no effect on nasal mucociliary
clearance in healthy volunteers.25 Other therapies, such as the administration of hypertonic saline, increase mucociliary
clearance in CF, but need to be studied in the ICU.26
Conclusion
In summary, patients in the ICU often need aggressive airway clearance. Many current therapies were established prior
to research demonstrating their effectiveness. In the absence of research, clinical experience and ICU protocols are often
called upon to decide which management strategies to use. Patients should be approached on a case-by-case basis prior
to the institution of unnecessary and potentially disruptive therapy.
Jon Steinfeld, MD, is assistant professor of pediatrics, Drexel University School of Medicine, St. Christopher’s Hospital for
Children, Philadelphia.
References
1. Hess DR. The evidence for secretion clearance techniques. Respir Care. 2001;46(11):1276-93.
2. Varekojis SM, Douce FH, Flucke RL, et al. A comparison of the therapeutic effectiveness of and preference for postural
drainage and percussion, intrapulmonary percussive ventilation, and high-frequency chest wall compression in
hospitalized cystic fibrosis patients. Respir Care. 2003;48(1):24-8.
3. Thomas J, Cook DJ, Brooks D. Chest physical therapy management of patients with cystic fibrosis. A meta-analysis.
Am J Respir Crit Care Med. 1995;15(3 Pt 1):846-50.
4. van der Schans C, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis.
Cochrane Database Syst Rev. 2000;(2):CD001401.
5. Wallis C, Prasad A. Who needs chest physiotherapy? Moving from anecdote to evidence. Arch Dis Child.
1999;80(4):393-7.
6. Orenstein DM. Heads up! Clear those airways! Pediatr Pulmonol. 2003;35(3):160-1.
7. Button BM, Heine RG, Catto-Smith AG, et al. Chest physiotherapy in infants with cystic fibrosis: to tip or not? A fiveyear study. Pediatr Pulmonol. 2003;35(3):208-13.
8. Berney S, Denehy L, Pretto J. Head-down tilt and manual hyperinflation enhance sputum clearance in patients who
are intubated and ventilated. Aust J Physiother. 2004;50(1):9-14.
9. Kluft J, Beker L, Castagnino M, Gaiser J, Chaney H, Fink RJ. A comparison of bronchial drainage treatments in cystic
fibrosis. Pediatr Pulmonol. 1996;22(4):271-4.
10. Langenderfer B. Alternatives to percussion and postural drainage. A review of mucus clearance therapies: percussion
and postural drainage, autogenic drainage, positive expiratory pressure, flutter valve, intrapulmonary percussive
ventilation, and high-frequency chest compression with the ThAIRapy Vest. J Cardiopulm Rehabil. 1998;18(4):283-9.
11. Winck JC, Goncalves MR, Lourenco C, Viana P, Almeida J, Bach JR. Effects of mechanical insufflation-exsufflation on
respiratory parameters for patients with chronic airway secretion encumbrance. Chest. 2004;126(3):774-80.
12. Miske LJ, Hickey EM, Kolb SM, Weiner DJ, Panitch HB. Use of the mechanical in-exsufflator in pediatric patients with
neuromuscular disease and impaired cough. Chest. 2004;125(4):1406-12.
13. Bar-Zohar D, Sivan Y. The yield of flexible fiberoptic bronchoscopy in pediatric intensive care patients. Chest.
2004;126(4):1353-9.
14. Frohock JI, Wijkstrom-Frei C, Salathe M. Effects of albuterol enantiomers on ciliary beat frequency in ovine tracheal
epithelial cells. J Appl Physiol. 2002;92(6):2396-2402.
15. Lindberg S, Khan R, Runer T. The effects of formoterol, a long-acting beta 2-adrenoceptor agonist, on mucociliary
activity. Eur J Pharmacol. 1995;285(3):275-80.
16. Dumasius V, Sznajder JI, Azzam ZS, et al. Beta2-adrenergic receptor overexpression increases alveolar fluid
clearance and responsiveness to endogenous catecholamines in rats. Circ Res. 2001;89(10):907-14.
17. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic
fibrosis sputum. Proc Natl Acad Sci U S A. 1990;87(23):9188-92.
18. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of
respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-42.
19. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant
human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993;342(8871):199-202.
20. Puchelle E, Zahm JM, de Bentzmann S, et al. Effects of rhDNase on purulent airway secretions in chronic bronchitis.
Eur Respir J. 1996;9(4):765-69.
21. Patel A, Harrison E, Durward A, Murdoch IA. Intratracheal recombinant human deoxyribonuclease in acute lifethreatening asthma refractory to conventional treatment. Br J Anaesth. 2000;84(4):505-7.
22. Durward A, Forte V, Shemie SD. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in
a mechanically ventilated child with refractory status asthmaticus. Crit Care Med. 2000;28(2):560-2.
23. Slattery DM, Waltz DA, Denham B, O’Mahony M, Greally P. Bronchoscopically administered recombinant human
DNase for lobar atelectasis in cystic fibrosis. Pediatr Pulmonol. 2001;31(5):383-8.
24. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Effects of drugs on mucus clearance. Eur Respir J.
1999;14(2):452-67.
25. Sisson JH, Yonkers AJ, Waldman RH. Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency
in healthy volunteers. Chest. 1995;107(3):747-51.
26. Wark PA, McDonald V. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev.
2003;(1):CD001506.